Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Informe acción SHSE:600196

Capitalización de mercado: CN¥63.5b

Salud financiera de hoja de balance de Shanghai Fosun Pharmaceutical (Group)

Salud financiera controles de criterios 4/6

Shanghai Fosun Pharmaceutical (Group) has a total shareholder equity of CN¥59.2B and total debt of CN¥32.6B, which brings its debt-to-equity ratio to 55%. Its total assets and total liabilities are CN¥115.3B and CN¥56.1B respectively. Shanghai Fosun Pharmaceutical (Group)'s EBIT is CN¥2.4B making its interest coverage ratio -1.4. It has cash and short-term investments of CN¥15.6B.

Información clave

55.0%

Ratio deuda-patrimonio

CN¥32.56b

Deuda

Ratio de cobertura de intereses-1.4x
EfectivoCN¥15.63b
PatrimonioCN¥59.19b
Total pasivoCN¥56.07b
Activos totalesCN¥115.26b

Actualizaciones recientes sobre salud financiera

Recent updates

Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year

Aug 03
Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year

Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden

Jul 28
Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden

Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

May 23
Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

May 01
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Apr 02
We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Mar 18
Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Feb 26
Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Análisis de la situación financiera

Pasivos a corto plazo: 600196's short term assets (CN¥34.5B) do not cover its short term liabilities (CN¥37.5B).

Pasivo a largo plazo: 600196's short term assets (CN¥34.5B) exceed its long term liabilities (CN¥18.6B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: 600196's net debt to equity ratio (28.6%) is considered satisfactory.

Reducción de la deuda: 600196's debt to equity ratio has reduced from 68.1% to 55% over the past 5 years.

Cobertura de la deuda: 600196's debt is not well covered by operating cash flow (12.1%).

Cobertura de intereses: 600196 earns more interest than it pays, so coverage of interest payments is not a concern.


Hoja de balance


Descubre empresas con salud financiera